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Abstract Glycyrrhizin (GL), a triterpenoid saponin fraction of
licorice, is reported to have anti-viral and anti-tumor activities
and is metabolized to 18L-glycyrrhetinic acid (GA) in the
intestine by intestinal bacteria. However, the mechanism under-
lying its effects is poorly understood. To further elucidate the
mechanism of GA, the aglycone of GL, we investigated the
effects of GA on the release of nitric oxide (NO) and at the level
of inducible NO synthase (iNOS) gene expression in mouse
macrophages. We found that GA elicited a dose-dependent
increase in NO production and in the level of iNOS mRNA.
Since iNOS transcription has been shown to be under the control
of the transcription factor nuclear factor UB (NF-UB), the effects
of GA on NF-UB activation were examined. Transient expres-
sion assays with NF-UB binding sites linked to the luciferase
gene revealed that the increased level of iNOS mRNA, induced
by GA, was mediated by the NF-UB transcription factor
complex. By using DNA fragments containing the NF-UB
binding sequence, GA was shown to activate the protein/
DNA binding of NF-UB to its cognate site, as measured by
electrophoretic mobility shift assay. These results demon-
strate that GA stimulates NO production and is able to up-
regulate iNOS expression through NF-UB transactivation in
macrophages. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
In immunocompetent hosts, the innate and adaptive arms
of the immune system are relatively e⁄cient at containing and
killing microbial pathogens. Nitric oxide (NO) is a radical
messenger molecule produced by the enzyme NO synthase
(NOS) [1]. Three NOS isoforms have been characterized:
the constitutively expressed neuronal NOS, endothelial NOS,
and the inducible isoform of NOS (iNOS). iNOS expression is
signi¢cantly induced by lipopolysaccharide (LPS) or cytokines
in a variety of immune cells, including macrophages [1].
Moreover, NO has been identi¢ed as the major e¡ector mol-
ecule involved in the destruction of microorganisms and tu-
mor cells by activated macrophages during the non-speci¢c
host defense of the immune system [2^5]. In contrast, with
these host protective actions, NO has also been implicated
as a mediator of tissue injury. As a host defense molecule,
NO also inhibits the proliferation of viruses, such as ectrome-
lia virus, coxsackie virus B3, cytomegaloviruses, and hepatitis
B virus [5^10]. In macrophages, nuclear factor UB (NF-UB) in
cooperation with other transcription factors has been found
to coordinate the expression of genes encoding iNOS. More-
over, NF-UB plays a critical role in the activation of immune
cells by up-regulating the expression of many cytokines essen-
tial for the immune response [11].
Licorice (Glycyrrhizza glabra L.) and its main water-soluble
constituent glycyrrhizin (GL), a pentacyclic triterpene deriva-
tive of the L-amyrin type (oleanane), have been widely used as
an antidote, demulcent and as a folk medicine for generations
in Asia and Europe, and it is currently used as a £avoring and
sweetening agent in food products. After oral administration
or intravenous injection, GL has been shown to be hydrolyzed
by the glucuronidase in intestinal bacteria to its active princi-
ple aglycone, 18L-glycyrrhetinic acid (GA), which is then ab-
sorbed into the blood [12]. GL and GA have been shown to
possess several bene¢cial pharmacological activities, which in-
clude an anti-ulcerative e¡ect, anti-in£ammatory activity, in-
terferon (IFN)-Q induction, and anti-hepatotoxicity e¡ect [13^
15]. Moreover, GL has also been described as an anti-viral
agent [16^18], and to have anti-tumor activity [19,20]. GL is
extensively used in Japan and is being examined in Europe in
patients with active and chronic hepatitis [21,22]. However,
the details of its mechanism remain unclear.
It is well known that the inducible production of NO by
macrophages inhibits the growth of many pathogens, includ-
ing bacteria, fungi, viruses, and parasites. Thus, it is possible
that GA-derived NO production may mediate the anti-viral
and anti-tumor activities of GA. To test this hypothesis, we
investigated the e¡ects of GA on NO production and the
molecular mechanisms underlying this e¡ect.
2. Materials and methods
2.1. Chemicals
Chemicals and cell culture materials were obtained from the follow-
ing sources: GA, Escherichia coli 0111:B4 LPS and polymyxin B sul-
fate from Sigma Co.; BAY 11-7082 from Biomol; MTT-based colori-
metric assay kit from Roche Co.; LipofectAMINE Plus, RPMI 1640,
fetal bovine serum, and penicillin^streptomycin solution from Life
Technologies, Inc.; pGL3-4UB-Luc and the luciferase assay system
from Promega; pCMV-L-gal from Clontech; and AmpliTaq0 DNA
polymerase from Perkin Elmer. Other chemicals were of the highest
commercial grade available.
2.2. Animals
Speci¢c pathogen-free BALB/C mice (female, 5^7 weeks old) were
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obtained from KRIBB (South Korea). Animals were housed under
normal laboratory conditions, i.e. at 21^24‡C and 40^60% relative
humidity under a 12 h light/dark cycle with free access to standard
rodent food and water.
2.3. Preparation of peritoneal macrophages and cell cultures
Peritoneal macrophages were isolated from mice and cultured as
described previously [23]. RAW 264.7 cells, a mouse macrophage
cell line, were obtained from the American Type Culture Collection
(Bethesda, MD, USA), and grown in RPMI 1640 supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 Wg/ml streptomycin at 37‡C in a 5% CO2 humidi¢ed incubator.
GA was dissolved in dimethylsulfoxide and added directly to the
culture media. Control cells were treated only with solvents, the ¢nal
concentration of which never exceeded 0.1%, and this concentration
did not show any e¡ect on the assay systems.
2.4. Cell viability
Cell viability was assessed using a MTT-based colorimetric assay kit
(Roche Co.), according to the manufacturer’s instructions.
2.5. Nitrite assay
Peritoneal macrophages (2U105 cells/ml) or RAW 264.7 cells
(5U105 cells/ml) were cultured in 48-well plates. After incubating
for 24 h, NO synthesis was determined by assaying the culture super-
natants for nitrite, the stable reaction product of NO with molecular
oxygen, using Griess reagent as described previously [23].
2.6. Endotoxin assay
An E-Toxate test (Limulus amebocyte lysate; Sigma Chemical Co.)
was used to assay GA for the presence of Gram-negative bacterial
endotoxin (LPS), according to the manufacturer’s instructions.
2.7. RNA preparation and iNOS mRNA analysis by reverse
transcription-polymerase chain reaction (RT-PCR)
RAW 264.7 cells were cultured with GA at a density of 1U106 cells/
ml for 6 h. Total cellular RNA was isolated by the acidic phenol
extraction procedure of Chomczynski and Sacchi [24]. cDNA synthe-
sis, semiquantitative RT-PCR for iNOS and L-actin mRNA, and the
analysis of results were performed as described previously [23]. cDNA
was synthesized from 2 Wg of total RNA using an Omniscript RT-
PCR kit as instructed. A cycle number was used that fell within the
exponential range of response for iNOS (754 bp, 35 cycles) and
L-actin (153 bp, 17 cycles). PCR reactions were electrophoresed
through a 2.5% agarose gel and visualized by ethidium bromide stain-
ing and UV irradiation. Gel images were captured on a Gel Doc
Image Analysis System (Kodak) and the yield of PCR products was
normalized to L-actin after quantitative estimation using NIH Image
software (Bethesda, MD, USA). The relative expression levels were
arbitrarily set at 1.0 in the control group.
2.8. Transfection and luciferase and L-galactosidase assays
RAW 264.7 cells (5U105 cells/ml) were plated in each well of a
12-well plate, and 12 h later transiently co-transfected with the plas-
mids pGL3-4UB-Luc and pCMV-L-gal, using LipofectAMINE Plus
according to the manufacturer’s protocol. Brie£y, the transfection
mixture containing 0.5 Wg of pGL3-4UB-Luc and 0.2 Wg of pCMV-
L-gal was mixed with the LipofectAMINE Plus reagent and added to
cells. After 18 h, the cells were treated with GA or LPS for 12 h, and
then lysed. Luciferase and L-galactosidase activities were determined
as described previously [23]. Luciferase activity was normalized using
L-galactosidase activity and was expressed relative to the activity of
the control.
2.9. Electrophoretic mobility shift assay
Nuclear extracts were prepared as previously described [25]. Two
double-stranded deoxyoligonucleotides containing the NF-UB binding
site (5P-GGGGACTTTCC-3P) [11] were end-labeled with [Q-32P]dATP.
Nuclear extracts (5 Wg) were incubated with 2 Wg of poly(dI-dC) and
the 32P-labeled DNA probe in binding bu¡er (100 mM NaCl, 30 mM
HEPES, 1.5 mM MgCl2, 0.3 mM EDTA, 10% glycerol, 1 mM dithio-
threitol, 1 mM phenylmethylsulfonyl £uoride, 1 Wg/ml each of apro-
tinin and leupeptin) for 10 min on ice. DNA was separated from the
free probe using a 4.8% polyacrylamide gel in 0.5UTBE bu¡er (44.5
mM Tris, 44.5 mM boric acid, and 1 mM EDTA). Following electro-
phoresis, the gel was dried and subjected to autoradiography.
2.10. Statistical analysis
All experiments were repeated at least three times. Student’s t-test
was used to assess the statistical signi¢cance of di¡erences. A con¢-
dence level of 6 0.01 was considered signi¢cant.
3. Results and discussion
As a host defense molecule, the inducible production of NO
by macrophages appears to be important in the elimination of
viruses and tumors [2^10]. Moreover, since GL is known to
have anti-viral and anti-tumor activity [16^20], we investi-
gated the e¡ects of GA on the NO production and its e¡ects
on the level of iNOS gene expression in mouse macrophages.
Our results demonstrate that GA stimulates NO production
and is able to up-regulate iNOS expression through NF-UB
transactivation. GA-induced NO production was assessed
after incubating for 24 h using the Griess reaction. The basal
level of NO in medium from untreated peritoneal macro-
phages was found to be less than 2 WM (Fig. 1). However,
upon GA stimulation, NO release by peritoneal macrophages
increased in a dose-dependent manner in the range 1^20 WM,
and showed a cytotoxic action upon macrophages at concen-
trations exceeding 30 WM (Fig. 1). The potent macrophage
activator LPS (0.5 Wg/ml), when used as immunostimulator,
increased NO production compared to the control. Consistent
Fig. 1. E¡ects of GA on NO production. Murine peritoneal macro-
phages (2U105 cells/ml) or RAW 264.7 cells (5U105 cells/ml) were
cultured for 24 h in the presence of media alone, with the indicated
concentrations of GA. NO production was determined by measuring
the accumulation of nitrite in the culture medium. Cell viability was
assessed by MTT assay. Each bar shows the mean þ S.D. of three
independent experiments, performed in triplicate. *P6 0.01, signi¢-
cantly di¡erent from the control.
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with these ¢ndings, GA also induced NO generation in a
dose-dependent manner in RAW 264.7 cells (Fig. 1). Based
on these results, and the relationship between NO and the
anti-viral and anti-tumor functions of macrophages, we sug-
gest that these e¡ects of GA might be mediated in part
through the activation of NO production.
Previous studies have shown that although GL alone did
not induce NO from resting or unstimulated macrophages,
NO production was enhanced in IFN-Q- or LPS-activated
macrophages isolated from GL-treated mice [20,26], which
suggested that GL has di⁄culty inducing NO production in
the absence of some other stimulation. This may be because
GL works synergistically with IFN-Q to induce NO produc-
tion of macrophages or because of the low sensitivity of the
assay. Moreover, it has been reported that GL enhances IFN-
Q production in mice [14]. We also observed that GL slightly
increased NO production in resting macrophages (data not
shown). In the present study, however, GA, the aglycone of
GL, signi¢cantly elicited a dose-dependent increase in NO
production in the absence of any stimulator. Unlike as in
previous studies [20,26], we did not need to co-stimulate
with IFN-Q or LPS to generate NO with GA. Moreover,
this GA-induced NO production was reversed when cells
were treated with both GA and with N-nitro-L-arginine meth-
yl ester, a competitive inhibitor of NOS (data not shown).
Therefore, GA, unlike GL, has the ability to increase NO
production alone in resting macrophages. The biological sig-
ni¢cance of the di¡erent e¡ects of GA and GL on NO pro-
duction in the resting and stimulated state needs to be deter-
mined.
Macrophages can be induced to produce NO by LPS or
cytokines [11]. To con¢rm that the observed ability of GA
to induce NO was not due to LPS contamination, the GA
was tested for the presence of contaminating LPS by using the
Limulus amebocyte lysate test. The level of LPS in GA was
found to be below the detection limit, which is typically below
12.5 pg/ml (data not shown). Polymyxin B sulfate has been
used previously as an LPS inhibitor in macrophage cultures
[27], and although GA contained no detectable activity in the
Limulus amebocyte lysate assay, we rechecked for possible
LPS contamination in GA by adding polymyxin B (10 Wg/
ml) to cell cultures treated with GA (10 WM). As shown in
Table 1, polymyxin B e¡ectively inhibited the NO production
induced by LPS, but had no e¡ect on the induction by GA,
which demonstrated that the production of NO by GA was
unlikely to have resulted from LPS contaminating the GA.
As stated above, GA induced macrophage secretion of NO.
In order to determine whether GA regulates NO production
at the mRNA level, an RT-PCR assay was conducted. LPS
was used as a positive control. Consistent with the results
obtained from the NO assay, iNOS mRNA levels were mark-
edly increased by GA treatment (Fig. 2). This result indicates
Table 1
E¡ects of polymyxin B on NO secretion by GA and LPS
Treatmenta Nitrite (WM)b
Control 1.98 þ 0.23*;**
GA 19.62 þ 2.23*
GA+polymyxin B 20.24 þ 2.27*
LPS 42.38 þ 6.31**
LPS+polymyxin B 8.43 þ 0.93*;**
aRAW 264.7 cells (5U105 cells/ml) cultured with GA (10 WM)
or LPS (0.5 Wg/ml), in the presence or absence of polymyxin B
(10 Wg/ml).
bSupernatants were harvested after being cultured for 24 h and as-
sayed for NO. Values are the means þ S.D. of three individual ex-
periments, performed in triplicate.
*P6 0.01, signi¢cantly di¡erent from the LPS. **P6 0.01, signi¢-
cantly di¡erent from the GA.
Fig. 2. E¡ects of GA on iNOS mRNA expression. RAW 264.7 cells
(1U106 cells/ml) were cultured for 6 h in the presence of media
alone, with the indicated concentrations of GA, or with LPS (0.5
Wg/ml). Cells were lysed and total RNA was prepared for the RT-
PCR analysis of gene expression. PCR ampli¢cation of the house-
keeping gene, L-actin, was performed for each sample. The PCR
ampli¢cation products were electrophoresed in 2.5% agarose gel and
stained with ethidium bromide. One of three representative experi-
ments is shown. The ratio of the RT-PCR products of iNOS to
L-actin was calculated. Induction-fold represents the mean þ S.D. of
three separate experiments. *P6 0.01, signi¢cantly di¡erent from
the control.
Fig. 3. E¡ects of GA on NF-UB-dependent luciferase gene expres-
sion. RAW 264.7 cells (5U105 cells/ml) were transiently co-trans-
fected with pGL3-4UB-Luc and pCMV-L-gal. After 18 h, cells were
treated with the indicated concentrations of GA or LPS (0.5 Wg/ml)
for 12 h. Cells were then harvested, and their luciferase and L-galac-
tosidase activities determined. Luciferase activities are expressed rel-
ative to the control. Each bar shows the mean þ S.D. of three inde-
pendent experiments, performed in triplicate. *P6 0.01, signi¢cantly
di¡erent from the control.
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that GA up-regulates NO accumulation in macrophages in a
dose-dependent manner. Therefore, we believe that increased
NO production by GA is regulated through transcriptional
activation.
Activated macrophages have the capacity to produce rela-
tively large quantities of NO and NO-derived species, such as
NOc2, NO
3
2 , N2O3, N2O4, S-nitrosothiols, and peroxynitrite
(ONOO3). Moreover, DNA and proteins are targets of reac-
tive nitrogen intermediates. In addition, nitrogen intermedi-
ates and reactive oxygen intermediates can synergistically in-
teract through the formation of peroxynitrites [28]. The
reactive nitrogen intermediates formed by NO play a signi¢-
cant role in tumoricidal and microbiocidal activities [3]. Cys-
teine proteases are critical for virulence or replication of many
viruses, bacteria, and parasites, and S-nitrosylation of patho-
gen cysteine proteases may be a general mechanism of the
antimicrobial host defenses [29]. In addition, NO has been
reported to interfere with speci¢c stages in the life cycles of
viruses. For example, NO inhibits DNA synthesis of the vac-
cinia virus and herpes simplex virus type 1, late protein trans-
lation, and virion assembly [30,31]. One speci¢c viral target of
NO has been identi¢ed; NO can inhibit the function and
expression of the Epstein^Barr virus immediate early trans-
activator Zta [32]. Since NO can inhibit a variety of viruses, it
is possible that NO also inhibits the cellular processes neces-
sary for viral replication.
NF-UB is a member of the Rel family, and is a common
regulatory element in the promoter region of many cytokines.
In activated macrophages, NF-UB, in synergy with other tran-
scriptional activators, plays a central role in coordinating the
expression of genes encoding iNOS, tumor necrosis factor-K,
and interleukin (IL)-1 [11]. To further investigate the role of
GA on iNOS gene expression, we assessed the e¡ect of GA on
NF-UB-dependent gene expression by using the luciferase re-
porter gene assay. RAW 264.7 cells were transiently trans-
fected with a plasmid containing four copies of the NF-UB
binding sites, and the luciferase activities were measured. LPS,
an immunostimulatory agent, was used as a positive control.
When cells were stimulated with LPS a near ¢ve-fold increase
in luciferase activity was observed versus the unstimulated
control cells. Consistent with NO production and iNOS
mRNA expression, GA also signi¢cantly increased NF-UB-
dependent luciferase activities in a dose-dependent manner
(Fig. 3). To further investigate the putative mechanism by
which GA activates iNOS, the e¡ect of GA on the activation
of a family of transcription factors was monitored by electro-
phoretic mobility gel shift assay. NF-UB binding activity was
examined in the light of its critical role in the regulation of
iNOS. The results demonstrated that GA induced a marked
increase in NF-UB binding at its conserved site, which was
visualized as a distinct band (Fig. 4). Recently, it has been
reported that GL treatment augmented IL-12 p40 mRNA
expression in mice and that this e¡ect may be associated
with NF-UB activation [33]. To further con¢rm the role of
NF-UB in iNOS expression by GA, we used BAY 11-7082,
an inhibitor of IUBK kinase, which speci¢cally inhibits NF-UB
activation by inhibiting the phosphorylation and the subse-
quent degradation of IUBK, the endogenous inhibitor of
NF-UB [34]. As shown in Fig. 5, pretreated RAW 264.7 cells
with BAY 11-7082 e¡ectively inhibited the NO production
induced by GA. Although we demonstrated the up-regulatory
e¡ect of GA on iNOS gene expression through NF-UB trans-
activation in macrophages, the mechanism by which GA acti-
vates NF-UB is unknown, such as the activation of Raf-1 and
mitogen-activated protein kinases [35]. Additional studies are
needed to answer these questions and further elucidate the
mechanisms involved.
GL has been widely and e¡ectively prescribed as a therapy
for chronic hepatitis [21,22]. Recently, it was reported that the
long-term treatment with GL for chronic hepatitis C e¡ec-
tively inhibited liver carcinogenesis [36]. Cellular immune re-
sponse has recently been shown to play an important role in
patients who have recovered from hepatitis C virus infection
Fig. 4. E¡ects of GA on NF-UB binding. RAW 264.7 cells were
treated with LPS (0.5 Wg/ml) or GA (10, 20 WM) for 1 h. Nuclear
extracts were isolated and used in an electrophoretic mobility shift
assay with 32P-labeled NF-UB oligonucleotide as a probe, as de-
scribed in Section 2. The arrow indicates the NF-UB binding com-
plex. Cold: 200-fold molar excess of non-labeled NF-UB probe. One
of three representative experiments is shown.
Fig. 5. E¡ects of NF-UB inhibition on NO production. RAW 264.7
cells (5U105 cells/ml) were pretreated with BAY 11-7082 for 1 h
and then cultured for 24 h in the presence of media alone, with the
indicated concentrations of GA. NO production was determined by
measuring the accumulation of nitrite in the incubation medium.
Each bar shows the mean þ S.D. of three independent experiments,
performed in triplicate. *P6 0.01, signi¢cantly di¡erent from the
control.
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[37]. Therefore, GL may activate certain immune functions,
and for this reason, it is important to elucidate the mecha-
nisms associated with the immunomodulatory activities of
GL. NO was investigated in the current study to con¢rm
the possibility that GA might be an immunostimulator, and
as a result, GA was found to elicit NO production. This result
supports the notion that NO induction by GA may contribute
in vivo to the immunomodulatory, anti-viral and anti-tumor
activity of GA. Biological response modi¢ers are widely used
in immunochemotherapy to potentiate therapeutic e⁄cacy or
to alleviate the toxicity of cytotoxic anti-cancer agents. Fur-
ther studies on GA are needed to prove its immunochemo-
therapeutic usefulness and its exact mechanism.
In summary, our results show for the ¢rst time that GA
stimulates macrophage-derived NO production, and is able to
up-regulate iNOS expression through NF-UB transactivation
in murine macrophages. These actions may provide a mecha-
nistic basis for the anti-viral and anti-tumor properties of GA.
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